Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics to Regain Rights to GDC-0919
Management to Host Conference Call Thursday, June 8 at 8:30 am ET
View HTML
Toggle Summary NewLink Genetics' Indoximod + PROVENGE® Results in Statistically Significant Improvement in Radiographic Progression-Free Survival (rPFS) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) in Phase 2 Trial
AMES, Iowa , June 05, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announces the presentation of results from a randomized Phase 2 investigator initiated study with indoximod in combination with the therapeutic cancer vaccine, PROVENGE (sipuleucel-T), for patients with
View HTML
Toggle Summary Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer
AMES, Iowa , June 02, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the results from a Phase 2 trial of indoximod in combination with taxane chemotherapy for patients with metastatic breast cancer.    Top line data from the study show that the trial did not
View HTML
Toggle Summary Data from Clinical Study of NewLink Genetics' IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress
AMES, Iowa , May 18, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic agents for patients with newly diagnosed acute myelogenous
View HTML
Toggle Summary Data from Clinical Studies of NewLink Genetics' Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017
AMES, Iowa , May 17, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and navoximod (GDC-0919), used in combination with other agents, are now available on the website of the 2017
View HTML
Toggle Summary NewLink Genetics to Participate in Upcoming Investor Conferences
AMES, Iowa , May 08, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) today announced that it will participate in the following upcoming investor conferences: Bank of America Merrill Lynch 2017 Health Care Conference on May 18 in Las Vegas, NV Jefferies 2017 Global Healthcare
View HTML
Toggle Summary NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance
Management to Host Conference Call Today at 8:30 a.m. ET
View HTML
Toggle Summary NewLink Genetics Announces Presentation of Two Abstracts at ASCO
AMES, Iowa , April 21, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported that two abstracts will be presented at the 2017 American Society of Clinical Oncology
View HTML
Toggle Summary NewLink Genetics to Host Its First Quarter 2017 Financial Results Conference Call on May 4, 2017
AMES, Iowa , April 13, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today announced that it will release its first quarter 2017 financial results on Thursday, May 4, 2017 . The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to
View HTML
Toggle Summary Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda® (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary
59% Objective Response Rate (ORR) and 80% Disease Control Rate (DCR) in 51 Patients with Non-ocular Melanoma
View HTML